PDF下载 ( 1525 KB)
Clinical features of HBV-associated acute-on-chronic liver failure induced by discontinuation of nucleoside analogues
-
摘要:
目的探讨停用核苷和核苷酸类药物导致HBV相关慢加急性肝衰竭（HBV-ACLF）患者的临床特点。方法回顾性分析2014年1月-2016年4月在解放军第三○二医院明确诊断为HBV-ACLF的患者698例,其中因停药导致ACLF的患者150例（停药组）,初次发病未行抗病毒治疗患者396例（初次未治组）,因其他原因导致ACLF的患者152例。统计所有患者发病诱因、基础疾病、家族史、乙型肝炎血清标志物、预后及是否为首次发病,对停用核苷和核苷酸类药物患者记录所用药物、停药至发生肝衰竭时间。计数资料组间比较采用χ2检验。结果 698例患者中355例（50.86%）有慢性乙型肝炎（CHB）家族史,停药组患者中93例（62.00%）有CHB家族史。停药组150例患者中27例（18.00%）为慢性肝炎基础,其中12例（44.44%）有CHB家族史,低于整体水平（χ2=2.57,P=0.07）;123例（82.00%）为肝硬化（代偿期）基础,其中81例（65.85%）有CHB家族史,显著高于整体水平（χ2=48.77,P<0.001）。...
Abstract:Objective To investigate the clinical features of patients with HBV- associated acute- on- chronic liver failure( HBV-ACLF) induced by the discontinuation of necleos( t) ide analogues. Methods A retrospective analysis was performed for 698 patients with a definite diagnosis of HBV- ACLF in The 302 Hospital of PLA from January 2014 to April 2016,and among these patients,150( discontinuation group) had acute- on- chronic liver failure( ACLF) induced by discontinuation,396( previously untreated group) had not received antiviral therapy when they developed this disease for the first time,and the other 152 patients with ACLF caused by other reasons were enrolled as controls. The causative factors,underlying diseases,family history,serum hepatitis B markers,prognosis,and initial onset were summarized,and the drugs used and discontinuation time were recorded for patients who stopped taking necleos( t) ide analogues. The chi-square test was used for the comparison of categorical data between groups. Results Among the 698 patients,355( 50. 86%) had a family history of chronic hepatitis B( CHB),and 93 patients( 62. 00%) in the discontinuation group had a family history of CHB. Among the 150 patients in the discontinuation group,27( 18. 00%) had an underlying disease of chronic hepatitis,among whom 12( 44. 44%) had a family history of CHB,which was significantly lower than the overall level( χ2= 2. 57,P = 0. 07); 123( 82. 00%) had an underlying disease of liver cirrhosis( compensated),among whom 81( 65. 85%) had a family history of CHB,which was significantly higher than the overall level( χ2= 48. 77,P < 0. 001). Of all the patients in the discontinuation group,77. 33%( 116/150) developed the disease within 1 year after discontinuation,and 21. 33%( 32/150) developed the disease during the second year after discontinuation. The HBe Ag- negative patients accounted for 47. 33%( 71/150). In the discontinuation group and previously untreated group,the patients with an underlying disease of chronic hepatitis showed a significantly higher cure and improvement rate than those with an underlying disease of liver cirrhosis( the discontinuation group: 88. 89% vs 53. 66%,χ2= 11. 450,P = 0. 001; the previously untreated group: 71. 79% vs 59. 50%,χ2= 5. 355,P =0. 021). Conclusion Discontinuation of necleos( t) ide analogues results in an increased proportion of patients with liver failure. Long-term antiviral therapy is very important,especially for patients with liver cirrhosis.
-
Key words:
- liver failure /
- hepatitis B virus /
- nucleosides /
- nucleotides
-
[1] LIU XY,HU JH,WANG HF,et al.Etiological analysis of 1977patients with acute liver failure,subacute liver failure and acuteon-chronic liver failure[J].Chin J Hepatol,2008,16(10):772-775.(in Chinese)刘晓燕,胡瑾华,王慧芬,等.1977例急性、亚急性、慢加急性肝衰竭患者的病因与转归分析[J].中华肝脏病杂志,2008,16(10):772-775. [2] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Disease,CMA;Severe Liver Disease and Artificial Liver Group,Chinese Society of Hepatology,CMA.Guideline for diagnosis and treatment of liver failure(2012 version)[J].Chin J Clin lnfect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝治疗组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327. [3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960. [4]XING HQ,ZOU ZS,CHEN JM,et al.Etiology,causative factors,and age distribution in patients with severe hepatitis and their association with prognosis[J].J Clin Intern Med,2003,20(1):47-48.(in Chinese)邢汉前,邹正升,陈菊梅,等.重型肝炎患者病因、诱因、年龄分布及其与预后的关系[J].临床内科杂志,2003,20(1):47-48. [5]LIU FF,SU HB,WANG HF,et al.Causes of HBV-related acute-on-chronic liver failure[J].Infect Dis Info,2010,23(3):161-164.(in Chinese)柳芳芳,苏海滨,王慧芬,等.HBV相关慢加急性肝衰竭发病诱因分析[J].传染病信息,2010,23(3):161-164. [6]GUO LW,WANG CY.Research advances in nucleos(t)ide analogues in treatment of acute-on-chronic liver failure caused by hepatitis B virus[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(5):707-709.(in Chinese)郭利伟,王昌源.核苷(酸)类似物治疗乙型肝炎病毒引起的慢加急性肝功能衰竭的研究进展[J/CD].中华实验和临床感染病杂志:电子版,2014,8(5):707-709. [7]LEVRERO M,POLLICINO T,PETERSEN J,et al.Control of ccc DNA function in hepatitis B virus infection[J].J Hepatol,2009,51(3):581-592. [8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ. [9]LIU BX.The research of HBV-specific T cells in chronic hepatitis B patient after antiviral therapy and stopping treatment with relapse[D].Nanchang:Nanchang Univ,2015.(in Chinese)刘碧霞.慢性乙肝患者抗病毒治疗与停药复发后体内HBV特异性T细胞的研究[D].南昌:南昌大学,2015. [10]PENG J,WANG C,ZHANG Q,et al.Association of HBe Ag positivity and alpha fetoprotein level with the prognosis of chronic severe hepatitis B[J].J South Med Univ,2008,28(10):1768-1770.(in Chinese)彭劫,王程,张琪,等.血清e抗原状态及甲胎蛋白水平对慢性重型乙型肝炎预后的影响[J].南方医科大学学报,2008,28(10):1768-1770. [11]CHEN N,XU QH,SHU X,et al.The clinic features and the short term efficacy of antiviral treatment on patients with HBe Ag negative chronic severe hepatitis B[J].China Clin Prac Med,2009,3(11):1-3.(in Chinese)陈旎,徐启桓,舒欣,等.HBe Ag阴性慢性乙型重型肝炎患者临床特征及抗病毒治疗后生存分析[J].中国临床实用医学,2009,3(11):1-3. [12]WEN B,YUAN J,LI XH,et al.The clinical features in chronic severe hepafitis B patients with HBe Ag-positive and HBe Ag-negative[J].Chin J Prim Med Pharm,2010,17(1):50-52.(in Chinese)文彬,袁静,李晓鹤,等.HBe Ag阳性与HBe Ag阴性慢性重型乙型肝炎死亡患者的临床特征比较[J].中国基层医药,2010,17(1):50-52. [13]HUANG SP,WANG FB.Pre-C mutants in 53 patients with chronic severe hepatitis B[J].J Pract Hepatol,2006,9(6):328-329.(in Chinese)黄绍萍,王冯滨.慢性乙型重型肝炎患者前C区变异株检测及对预后的影响[J].实用肝脏病杂志,2006,9(6):328-329. [14]LIU XY,HU JH,WANG HF.Analysis of prognostic factors for patients with acute-on-chronic liver failure[J].Chin J Hepatol,2009,17(8):607-610.(in Chinese)刘晓燕,胡瑾华,王慧芬.乙型肝炎病毒感染所致慢加急性肝衰竭的临床预后分析[J].中华肝脏病杂志,2009,17(8):607-610. [15]QIU B,ZHU L,WANG TM,et al.Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure[J].J Clin Hepatol,2016,32(7):1300-1304.(in Chinese)邱波,朱玲,王堂明,等.小剂量糖皮质激素治疗HBV相关慢加急性肝衰竭的效果观察[J].临床肝胆病杂志,2016,32(7):1300-1304. 期刊类型引用(12)
1. 郭龙鑫，高云娟，吴承钊，龙敏娟，祝胜凯，宋海波，赵旭，肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探. 中国药物警戒. 2024(01): 15-19 . 
百度学术2. 李勇，张蕾，吴幸福. 老年药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2024(04): 547-550 . 百度学术3. 徐媛，方忠宏，冉姗. 1例多因素所致药物性肝损伤病例的病因论证与药学监护. 药物流行病学杂志. 2023(03): 350-355 . 百度学术4. 郭冬伟. 生物技术药物的免疫毒性和免疫原性的分析及探讨. 当代化工研究. 2021(03): 161-162 . 百度学术5. 李任，苏庆全，黎运. 62例肺结核患者抗结核药物治疗致药物性肝损伤的危险因素分析及其防治对策. 抗感染药学. 2021(05): 724-726 . 百度学术6. 杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 . 百度学术7. 王巧玲，邹正升. 细胞色素P450基因多态性与药物性肝损伤的关系. 临床肝胆病杂志. 2020(05): 1150-1153 . 
本站查看8. 许维国. 中草药导致药物性肝损伤的现状及研究进展. 中国处方药. 2020(06): 14-16 . 百度学术9. 刘毅，周淑娴，陈念辉. 1例药源性肝损伤合并2型糖尿病患者的病例分析. 中国药师. 2020(10): 1986-1989 . 百度学术10. 陈龙，李钺. 肝切除术后并发症的危险因素及预测评分系统. 临床肝胆病杂志. 2019(01): 217-221 . 本站查看11. 郭永涛. 抗肺结核药物所致肝损伤患者临床症状分布及危险因素分析. 山西医药杂志. 2019(05): 564-566 . 百度学术12. 刘丽艳，唐晓雯，董春玲，陶茹，刘成海，张雅丽. 药物性肝损伤患者的护理研究进展. 护士进修杂志. 2019(24): 2253-2256 . 百度学术其他类型引用(8)
-
百度学术
下载:
